Clinical trial
Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for…
NCT00392314 · Rambam Health Care Campus, Other · Completed
Key facts
| NCT number | NCT00392314 |
|---|---|
| Title | Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. |
| Official title | Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions. |
| Lead sponsor | Rambam Health Care Campus, Other |
| Collaborators | Hadassah Medical Organization Rabin Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin Lymphoma |
| Intervention type | Other |
| Interventions | PET/CT post 2 cycles of chemotherapy |
| Enrollment | 365 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Oct 26, 2006 |
| Last update posted | May 9, 2014 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: